Administration of Cyclophosphamide Changes the Immune Profile of Tumor-bearing Mice
- 1 January 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Immunotherapy
- Vol. 33 (1), 53-59
- https://doi.org/10.1097/cji.0b013e3181b56af4
Abstract
Cyclophosphamide (CTX) is often used to create a “window” for more effective therapeutic tumor vaccination. According to a commonly applied protocol, we injected 2 mg CTX intraperitoneally to mice with small (2 to 3 mm diameter) or large (5 to 7 mm, and in one experiment 8 to 10 mm diameter) subcutaneously growing tumors from the SW1 clone of the K1735 melanoma, euthanized the mice 4 days later and studied the composition of lymphoid cells by flow cytometry in both spleens and tumors. Administration of CTX increased the percentage of CD3+, CD4+, and CD8+ cells with the increase in tumors being significantly greater than in spleens, and it also increased the percentage of B cells in spleens and tumors. Furthermore, CTX dramatically increased the frequency of tumor-infiltrating CD4 and CD8 cells containing interferon γ, of cells expressing NK1.1, and of cells expressing the dendritic cell markers CD11c, CD80, and CD86, with the greatest increases seen among tumor-infiltrating lymphoid cells (TIL) from mice with small tumors. Although CTX decreased the percentage of TIL that expressed CD4 or CD8 together with CD25 and FoxP3 and were therefore considered to be regulatory T cells, it increased the frequency of TIL that stained for Gr1/CD11b, a marker for myeloid-derived suppressor cells. We conclude that the administration of CTX can favorably impact several cell populations that are involved in tumor rejection. However, since CTX has a limited effect on TIL from tumors larger than a few millimeter in diameter and in view of an increased percentage of myeloid-derived suppressor cells among TIL from mice given CTX there is a need for more effective ways to improve tumor vaccination.Keywords
This publication has 36 references indexed in Scilit:
- Lack of Muc1-Regulated β-Catenin Stability Results in Aberrant Expansion of CD11b+Gr1+ Myeloid-Derived Suppressor Cells from the Bone MarrowCancer Research, 2009
- Inhibition of TGFβ1 Makes Nonimmunogenic Tumor Cells Effective for Therapeutic VaccinationJournal of Immunotherapy, 2009
- High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate TherapyClinical Cancer Research, 2008
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy, 2008
- Vaccines to treat cancer‐an old approach whose time has arrivedJournal of Cellular Biochemistry, 2007
- Cancer Immunologists and Cancer Biologists: Why We Didn't Talk Then but Need to NowCancer Research, 2007
- Tumor Cells Expressing Anti-CD137 scFv Induce a Tumor-Destructive EnvironmentCancer Research, 2007
- Human cancers express a mutator phenotypeProceedings of the National Academy of Sciences of the United States of America, 2006
- Effect of Adenovirus-Mediated Heat Shock Protein Expression and Oncolysis in Combination with Low-Dose Cyclophosphamide Treatment on Antitumor Immune ResponsesCancer Research, 2006
- Mouse CD11c+ B220+ Gr1+plasmacytoid dendritic cells develop independently of the T-cell lineageBlood, 2002